# Furmonertinib

Source: https://onco.cc/drugs/furmonertinib/  
OnCo record `furmonertinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial.

## Summary

Developed by Shanghai Allist Pharmaceuticals; approved by the NMPA in March 2021 for EGFR T790M-positive NSCLC after earlier EGFR inhibitors and in June 2022 for first-line EGFR-mutant NSCLC on FURLONG (358 patients: median progression-free survival 20.8 versus 11.1 months with gefitinib, hazard ratio 0.44). A higher dose is being developed for EGFR exon 20 insertions, where ArriVent BioPharma holds ex-China rights and is running the global FURVENT phase 3 trial. Adjuvant and central nervous system studies continue.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Tags: china
- Brand: Ivesa
- Code: AST2818, alflutinib
- Modality: Small-molecule third-generation EGFR TKI
- Mechanism: Irreversible third-generation EGFR inhibitor active against sensitising mutations and T790M with a trifluoroethoxy pyridine that improves brain penetration; its main metabolite is also active.
- Approvals: China 2021: EGFR T790M-positive locally advanced or metastatic NSCLC after EGFR TKI therapy; China 2022: First-line EGFR exon 19 deletion or L858R NSCLC (FURLONG)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Furmonertinib
- Shanghai Allist Pharmaceuticals: https://www.allist.com.cn/
- FURLONG (Lancet Respir Med 2022): https://doi.org/10.1016/S2213-2600(22)00168-0
- NMPA (National Medical Products Administration): https://www.nmpa.gov.cn

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [ArriVent BioPharma](https://onco.cc/companies/arrivent/), [Minghui Pharmaceutical](https://onco.cc/companies/minghui-pharmaceutical/), [Shanghai Allist Pharmaceuticals](https://onco.cc/companies/allist/)
- pathways: [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- terms: [EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)](https://onco.cc/terms/egfr-mutation-subtypes/)
- trials: [A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv](https://onco.cc/trials/nct06962865/), [A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases](https://onco.cc/trials/nct06970639/), [A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer](https://onco.cc/trials/nct07229599/), [A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct07622186/), [Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion](https://onco.cc/trials/nct05466149/), [FURLONG](https://onco.cc/trials/furlong/), [Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations](https://onco.cc/trials/nct06674343/), [Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA](https://onco.cc/trials/nct05334277/), [IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC](https://onco.cc/trials/nct05994131/), [Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With](https://onco.cc/trials/nct05607550/), [Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W](https://onco.cc/trials/nct07185997/), [To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy](https://onco.cc/trials/nct04853342/)

---
JSON: https://onco.cc/api/v1/entities/furmonertinib.json